Immuron Limited
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving Immuron Limited now
Current reporting with the operating signal separated from the noise.
Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.90 Price Target
The development tests whether Immuron Limited can turn product investment into adoption, revenue and durable advantage.
Watch next: confirmation in a company filing, official release or regulator record.Immuron Limited: Immuron Reports HY26 Results and Strategic Reset
The story matters when it changes Immuron Limited’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Immuron Limited Reports Strong Sales Projections and Updates on Clinical Trials and Product Launches
The development tests whether Immuron Limited can turn product investment into adoption, revenue and durable advantage.
Watch next: official volume, pricing, inventory and segment margin.Immuron Limited Submits Phase 2 Clinical Study Report for Travelan® (IMM-124E) to FDA, Achieving Significant Immunology and Microbiome Results
The story matters when it changes Immuron Limited’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Immuron Limited (IMRN) Q4 2022 Earnings Call Transcript
Investors are testing whether Immuron Limited’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.How Much Are Immuron Limited (ASX:IMC) Insiders Spending On Buying Shares?
Investors are testing whether Immuron Limited’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Latest IMRN filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
Immuron Limited, quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →Third quarter
No verified period-specific item in the current feed.
SEARCH Q3 COVERAGE →